ERBB2 and breast carcinoma: Additionally, results from the phase III PHEDRA trial demonstrated clinical benefits of pyrotinib plus trastuzumab and docetaxel for patients with HER2-positive early or locally advanced breast cancer in the neoadjuvant setting (Chan et al., 2016).